Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind crossover study

Diabetes Care

Volumn 25, Issue 1, 2002, Pages 95-100

  Rossing, Kasper ^a   Christensen, Per K ^a   Jensen, Berit R ^a   Parving, Hans Henrik ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOGLOBULIN G; PLACEBO; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CREATININE; PRODRUG; TETRAZOLE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMOGRAPHY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DOWN REGULATION; GEOMETRY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; METHODOLOGY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE LEVEL; ALBUMINURIA; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CREATININE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIURETICS; DOUBLE-BLIND METHOD; GLOMERULAR FILTRATION RATE; HUMANS; PATIENT COMPLIANCE; PLACEBOS; PRODRUGS; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 0036369626     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.1.95     Document Type: Article

References (36)

1. Parving H-H, Østerby R, Ritz E: Diabetic nephropathy. In The Kidney. 6th ed. Brenner BM, Levine S, Eds. Philadelphia, WB Saunders, 2000, p. 1731-1773
2. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica D, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolten WK: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 45 (Suppl. 45):S150-S155, 1994
3. Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112:707-708, 1990
4. Nielsen FS, Rossing P, Gall M-A, Skott P, Smidt UM, Parving H-H: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182-1188, 1997
5. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, Lusardi P: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47-53, 1999
6. Nussberger J, Brunner DB, Waeber B, Brunner HR: Plasma angiotensins under sustained converting enzyme inhibition with enalapril in normal humans. J Hypertens Suppl 3 (Suppl. 3):S269-S270, 1985
7. Hollenberg NK, Fisher NDL, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32:387-392, 1998
8. World Health Organization: Diabetes Mellitus, Report of a WHO Study Group. Geneva, World Health Org., 1985
9. Parving H-H, Gall M-A, Skott P, Jorgensen HE, Lokkegaard H, Jorgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41:758-762, 1992
10. Brochner-Mortensen J, Rödbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36:35-45, 1976
11. Bröchner-Mortensen J: A simple method for the determination of glomerular filtration rate. Scand J Clin Lab Invest 30:271-274, 1972
12. 51Cr]EDTA. Scand J Clin Lab Invest 36:247-249, 1976
13. Fomsgaard A, Feldt-Rasmussen B, Decken M, Dinesen B: Micro-ELISA for the quantitation of human urinary IgG: technical note. Scand J Clin Lab Invest 47:195-198, 1987
14. Maroni BJ, Steinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 27:58-65, 1985
15. Kappelgaard AM, Nielsen MD, Giese J: Measurement of angiotensin II in human plasma: technical modifications and practical experience. Clin Chim Acta 67:299-306, 1976
16. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF: Safety of the combination of valsartan and benazepril in patients with chronic renal disease: European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89-95, 2000
17. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 321:1440-1444, 2000
18. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H: Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47:1726-1731, 1995
19. Hommel E, Parving H-H, Mathiesen ER, Edsberg B, Nielsen MD, Giese J: Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br Med J 293:466-470, 1986
20. Lewis E, Hunsicker L, Bain R, Rhode R: The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
21. Gomez HJ, Cirillo VJ, Sromovsky JA, Otterbein ES, Shaw WC, Rush JE, Chrysant SG, Gradman AH, Leon AS, MacCarthy EP, Nelson EB, Pool J, Vedin A: Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 28:415-420, 1989
22. Sassano P, Chatellier G, Billaud E, Corvol P, Menard J: Comparison of increase in the enalapril dose and addition of hydrochlorothiazide as second-step treatment of hypertensive patients not controlled by enalapril alone. J Cardiovasc Pharmacol 13:314-319, 1989
23. Lijnen P, Fagard R, Staessen J, Verschueren LJ, Amery A: Dose response in captopril therapy of hypertension. Clin Pharmacol Ther 28:310-315, 1980
24. Eber B, Brussee H, Rotman B, Kramer R, Klein W: Evaluation of the antihypertensive effect of lisinopril compared with nifedipine in patients with mild to severe essential hypertension. Angiology 43:482-489, 1992
25. Agarwal R: Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int 59:2282-2289, 2001
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:910-912, 2001
27. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344:1351-1357, 2001
28. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving H-H: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
29. Verme-Gibboney C: Oral angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 54:2689-2703, 1997
30. Parving H-H: Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 41:745-759, 1998
31. Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 45:S145-S149, 1994
32. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
33. Apperloo AJ, de Zeeuw D, de Jong PE: Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with nondiabetic renal disease. Kidney Int Suppl 45:S174-S178, 1994
34. Parving H-H, Lehnert H, BröchnerMortensen J, Gomis R, Andersen S, Amer P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878 2001
35. Andersen S, Blouch K, Bialek J, Deckert M, Parving HH, Myers BD: Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 58:2129-2137, 2000
36. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317:703-713, 1998